Guardant Health (NASDAQ:GH) shares added ~15% premarket Friday as the stock resumed trading after an FDA advisory committee backed the company's Shield colorectal cancer (CRC) screening test, paving ...
Source LinkGuardant Health (NASDAQ:GH) shares added ~15% premarket Friday as the stock resumed trading after an FDA advisory committee backed the company's Shield colorectal cancer (CRC) screening test, paving ...
Source Link
Comments